New IPECAD open-source model framework for the health technology assessment of early Alzheimer’s disease treatment: development and use cases

Abstract

Objectives Market access and reimbursement decisions for new Alzheimer’s disease (AD) treatments are informed by economic evaluations. An open-source model with intuitive structure for model cross-validation can support the transparency and credibility of such evaluations. We describe the new IPECAD open-source model framework (version 2) for the health-economic evaluation of early AD treatment and use it for cross-validation and addressing uncertainty.